Related Experiment Video
Updated: Apr 6, 2026

Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
Natriuretic Peptides and the Management of Heart Failure
Tyler Kern, Ilan Kedan, Asher Kimchi1
1David Geffen School of Medicine at UCLA, Los Angeles, CA; Cedars-Sinai Heart Institute, Los Angeles, CA.
Abstract:
Natriuretic peptide has been validated as a useful biomarker in the diagnosis of heart failure, although its role in guiding medical management of heart failure is not well established. We endeavored to determine if natriuretic peptide-guided therapy is associated with improved outcomes for heart failure patients. A total of 11 trials (2628 patients) comparing natriuretic peptide-guided therapy with standard therapy for heart failure patients were identified; follow-up times ranged from 3 months to 3 years. Our data indicate that natriuretic peptide levels and all-cause mortality rates do not appear to benefit from natriuretic peptide-guided therapy when compared with standard therapy. However, a decreased rate of cardiovascular events does appear to be associated with natriuretic peptide-guided therapy.
Related Concept Videos
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Heart Failure II: Pathophysiology
Heart Failure VII: Nursing Interventions
Mitral Regurgitation IV: Nursing Management

